These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 27320527)

  • 1. [Therapeutic inhibition of platelets in acute coronary syndrome and in coronary intervention: mechanisms and clinical results].
    Peter K; Nordt T; Bode C
    Z Kardiol; 2000 Oct; 89(Suppl 7):60-9. PubMed ID: 27320527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic inhibition of platelets in a acute coronary syndrome and in coronary intervention: mechanisms and clinical results].
    Peter K; Nordt T; Bode C
    Z Kardiol; 2000; 89 Suppl 7():60-9. PubMed ID: 11098561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome.
    Yakushkin VV; Zyuryaev IT; Khaspekova SG; Sirotkina OV; Ruda MY; Mazurov AV
    Platelets; 2011; 22(4):243-51. PubMed ID: 21329420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
    Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
    Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art.
    Tan HC; Harrington RA; Tcheng JE
    J Thromb Thrombolysis; 1997; 4(3/4):431-439. PubMed ID: 10639648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
    J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
    Chiang TM; Zhu J
    Thromb Res; 2005; 115(6):503-8. PubMed ID: 15792682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Which, when, how?].
    Juárez Herrera U
    Arch Cardiol Mex; 2001; 71 Suppl 1():S85-90. PubMed ID: 11565353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK; Whitaker DA; Sobel BE; Schneider DJ
    Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns.
    Hoekstra JW; Roe MT; Peterson ED; Menon V; Mulgund J; Pollack CV; Miller C; Palabrica T; Harrington RA; Ohman EM; Gibler WB
    Acad Emerg Med; 2005 May; 12(5):431-8. PubMed ID: 15863399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactive oxygen species and human platelet GP IIb/IIIa receptor activation.
    Sill JC; Proper JA; Johnson ME; Uhl CB; Katusic ZS
    Platelets; 2007 Dec; 18(8):613-9. PubMed ID: 18041653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of an antibody to the integrin beta 3 subunit (GP IIIa) from a patient with neonatal thrombocytopenia and an inherited deficiency of GP IIb-IIIa complexes in platelets (Glanzmann's thrombasthenia).
    Jallu V; Pico M; Chevaleyre J; Vézon G; Kunicki TJ; Nurden AT
    Hum Antibodies Hybridomas; 1992 Apr; 3(2):93-106. PubMed ID: 1633270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
    Furman MI; Krueger LA; Linden MD; Barnard MR; Frelinger AL; Michelson AD
    J Am Coll Cardiol; 2004 Jun; 43(12):2319-25. PubMed ID: 15193700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes.
    Lepor NE
    Rev Cardiovasc Med; 2002; 3 Suppl 1():S3-S12. PubMed ID: 12439431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective use of platelet glycoprotein IIb/IIIa receptor blockers in the emergency department setting.
    Gibler WB; Wilcox RG; Bode C; Castaigne AD; Delooz H; Elich D; Fox KA; Kereiakes DJ; Rupprecht H; Topol EJ
    Eur J Emerg Med; 1998 Dec; 5(4):391-402. PubMed ID: 9919443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.